| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2022: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Keloid-derived fibroblasts cultured in the presence of TGF-β1 were co-cultured with ADSCs. Immunofluorescence microscopy, real-time polymerase chain reaction, and western blotting were performed to determine the expression levels of smooth muscle protein 22-α (SM22α), type I collagen (COL1), TGF-β1, matrix metallopeptidase 2 (MMP2), SMAD2, SMAD3, platelet-derived growth factor receptor α (PDGFRα), and TGF-β receptor type-1 (TGFβR1). Keloid-derived fibroblast-embedded collagen gel contraction assay was also performed. As a result, keloid-derived fibroblasts expressed SM22α, COL1, TGF-β1, MMP2, SMAD2, SMAD3, PDGFRα, and TGFβR1. TGF-β1 increased their expression levels, whereas ADSCs significantly suppressed them. TGF-β1 induced the contraction of keloid-derived fibroblast-embedded collagen gel, whereas ADSCs significantly inhibited it. ADSCs antagonize the fibrotic effects of TGF-β1 on keloid-derived fibroblasts.
|
